Literature DB >> 28434930

Enhancing targeted antibiotic therapy via pH responsive solid lipid nanoparticles from an acid cleavable lipid.

Rahul S Kalhapure1, Dhiraj R Sikwal2, Sanjeev Rambharose2, Chunderika Mocktar2, Sanil Singh3, Linda Bester3, Jung Kwon Oh4, Jwala Renukuntla5, Thirumala Govender6.   

Abstract

An acid cleavable lipid (SA-3M) was synthesized and used to develop pH-responsive solid lipid nanoparticles (SLNs) to deliver vancomycin base (VM-FB) to acidic infection sites. The size, polydispersity index and zeta potential of VM-FB_SA-3M_SLNs were 132.9±9.1nm, 0.159±0.01 and -26±4.4mV respectively, with 57.80±1.1% encapsulation efficiency. VM-FB release was significantly faster at pH6.5 than pH7.4. In vitro antibacterial activity against methicillin-susceptible and resistant Staphylococcus aureus (MSSA and MRSA) revealed that SLNs had enhanced activity at pH6.5 than pH7.4. In vivo study showed that the amount of MRSA remaining in the skin of VM-FB_SA-3M_SLNs treated mice was approximately 22-fold lower than VM-FB treated mice. Histological investigations revealed that signs of inflammation in the skin treated with VM-FB_SA-3M_SLNs were minimal. In conclusion, this study confirmed that SA-3M can form pH-responsive SLNs capable of releasing antibiotic specifically at acidic infection sites.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Methicillin-resistant S. aureus; Solid lipid nanoparticles; Targeted delivery; Vancomycin; pH-responsive

Mesh:

Substances:

Year:  2017        PMID: 28434930     DOI: 10.1016/j.nano.2017.04.010

Source DB:  PubMed          Journal:  Nanomedicine        ISSN: 1549-9634            Impact factor:   5.307


  7 in total

Review 1.  Nanoparticle, a promising therapeutic strategy for the treatment of infective endocarditis.

Authors:  Qi Tong; Tao Li; Lu Jiang; Zhengjie Wang; Yongjun Qian
Journal:  Anatol J Cardiol       Date:  2022-02       Impact factor: 1.596

Review 2.  Application of Nanomaterials in the Prevention, Detection, and Treatment of Methicillin-Resistant Staphylococcus aureus (MRSA).

Authors:  John Hulme
Journal:  Pharmaceutics       Date:  2022-04-06       Impact factor: 6.525

Review 3.  Nano-fats for bugs: the benefits of lipid nanoparticles for antimicrobial therapy.

Authors:  Chelsea R Thorn; Nicky Thomas; Ben J Boyd; Clive A Prestidge
Journal:  Drug Deliv Transl Res       Date:  2021-03-05       Impact factor: 4.617

Review 4.  A review on nanosystems as an effective approach against infections of Staphylococcus aureus.

Authors:  Kaixiang Zhou; Chao Li; Dongmei Chen; Yuanhu Pan; Yanfei Tao; Wei Qu; Zhenli Liu; Xiaofang Wang; Shuyu Xie
Journal:  Int J Nanomedicine       Date:  2018-11-09

5.  Formulation development of linagliptin solid lipid nanoparticles for oral bioavailability enhancement: role of P-gp inhibition.

Authors:  Pranav Shah; Kejal Chavda; Bhavin Vyas; Shailaja Patel
Journal:  Drug Deliv Transl Res       Date:  2021-06       Impact factor: 4.617

Review 6.  Incorporation of Antibiotics into Solid Lipid Nanoparticles: A Promising Approach to Reduce Antibiotic Resistance Emergence.

Authors:  Lide Arana; Lucia Gallego; Itziar Alkorta
Journal:  Nanomaterials (Basel)       Date:  2021-05-10       Impact factor: 5.076

Review 7.  Recent advances in the treatment of pathogenic infections using antibiotics and nano-drug delivery vehicles.

Authors:  Vo Van Giau; Seong Soo A An; John Hulme
Journal:  Drug Des Devel Ther       Date:  2019-01-18       Impact factor: 4.162

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.